Devon Energy Corp vs TransMedics Group Inc — how do they compare? Devon Energy Corp trades at $42.99 (market cap $50.44B), while TransMedics Group Inc trades at $75.99 (market cap $2.58B). The key difference: Devon Energy Corp is far larger — about 19.6× TransMedics Group Inc's market cap, and Devon Energy Corp pays a 2.38% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| DVN | TMDX | |
|---|---|---|
Market Cap | $50.44B | $2.58B |
Sector | Energy | Technology |
52-Week High | $52.07 | $150.42 |
52-Week Low | $31.74 | $61.99 |
Enterprise Value | $57.22B | $2.98B |
Dividend Yield | 2.38% | — |
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $43.73, up 3.55% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026, with Q2 results pending. The company maintains solid profitability with a 13.71% net margin and robust cash flow, supported by the Coterra acquisition targeting $2 billion in synergies by 2027. Debt-to-asset ratio improved to 26.54% in 2025, reflecting disciplined financial management.
Outlook remains positive with a consensus price target of $60.55, implying significant upside. Key opportunities include synergy realization and free cash flow growth, while risks involve oil price volatility and activist investor pressure for asset sales. The stock offers value with a P/E of 12.18, below sector averages, but investors should monitor Q2 earnings due August 4 for confirmation of growth trajectory.
TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.
The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.
Trailing returns across standard periods
Latest headlines on both assets
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →